Stacey Johnson
Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.
Posts by: Stacey
As June comes to an end, so does Pride Month in Canada. In 12 years of blogging for Signals, I realize I have never covered the topic of STEM (science, technology, engineering and mathematics) and Pride, although I have written about Equity, Diversity and Inclusion (EDI) and featured EngiQueers, founded at McMaster University. In the […]
Dr. Michel Sadelain, the “inventor of T cells” and a graduate of the University of Alberta, has won the 2024 Breakthrough Prize in life sciences. After completing his medical degree at the University of Paris, Dr. Sadelain earned his PhD in immunology at the University of Alberta, before moving to the Massachusetts Institute of Technology […]
Today is World Water Day, an observance that the United Nations has been recognizing since 1993. What does water have to do with regenerative medicine? Stick with me. (And no, I’m not going to talk about hydrogels.) World Water Day was established to raise awareness of the 2.2 billion people living without access to safe […]
Today is International Women’s Day (IWD). If you are tired of hearing about the lack of gender equality in science, technology, engineering and mathematics (STEM), this post is not for you. If it makes you tired that in 2024 this remains an issue, read on. We all have a role to play in closing the […]
As a fair-skinned, freckled person (my mom says she painted them on me while I slept), and one who has a family history of skin cancers and melanoma, the news on February 19 that Iovance Biotherapeutics’ AMTAGVITM received U.S. Food and Drug Administration (FDA) accelerated approval to treat melanoma was welcome news to me and […]
Right Turn: STEM and Pride
As June comes to an end, so does Pride Month in Canada. In 12 years of blogging for Signals, I realize I have never covered the topic of STEM (science, technology, engineering and mathematics) and Pride, although I have written about Equity, Diversity and Inclusion (EDI) and featured EngiQueers, founded at McMaster University. In the […]